Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jun 30;13(6):1432-1437.
doi: 10.21037/tlcr-24-185. Epub 2024 Jun 25.

The APPLE trial in the evolving landscape of ctDNA monitoring

Danielle Brazel  1 , Misako Nagasaka  2   3
Affiliations
Editorial

The APPLE trial in the evolving landscape of ctDNA monitoring

Danielle Brazel et al. Transl Lung Cancer Res. .
No abstract available

Keywords: EGFR mutations; T790M; circulating tumor DNA (ctDNA); switch to osimertinib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-185/coif). M.N. is a member of these advisory boards: AstraZeneca, Daiichi Sankyo, Takeda, Novartis, EMD Serono, Janssen, Pfizer, Eli Lilly and Company, Bayer, Regeneron, BMS, and Genentech; a consultant at Caris Life Sciences (virtual tumor board); a speaker at Blueprint Medicines, Janssen, Mirati and Takeda; and reports travel support from AnHeart Therapeutics and stock/stock options from MBrace Therapeutics. The other author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Study schema of the APPLE study. ctDNA, circulating tumor DNA; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; brain mets, brain metastases; NSCLC, non-small cell lung cancer; PD, disease progression; PFS, progression-free survival; N, number; R, randomized; RECIST, response evaluation criteria in solid tumors.
Figure 2
Figure 2
Comparison of subsequent therapies received in the APPLE study (arm B, arm C) and FLAURA. ctDNA, circulating tumor DNA; RECIST, response evaluation criteria in solid tumors; TKI, tyrosine kinase inhibitor.
See this image and copyright information in PMC

Comment on

References

    1. Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016;387:1415-26. 10.1016/S0140-6736(16)00004-0 - DOI - PubMed
    1. Reguart N, Remon J. Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors. Future Oncol 2015;11:1245-57. 10.2217/fon.15.15 - DOI - PubMed
    1. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240-7. 10.1158/1078-0432.CCR-12-2246 - DOI - PMC - PubMed
    1. Mok T, Wu YL, Lee JS, et al. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clin Cancer Res 2015;21:3196-203. 10.1158/1078-0432.CCR-14-2594 - DOI - PubMed
    1. Sorensen BS, Wu L, Wei W, et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer 2014;120:3896-901. 10.1002/cncr.28964 - DOI - PMC - PubMed

LinkOut - more resources